You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Evolution of the Gynecologic Oncology Group Protocols in the Treatment of Epithelial Ovarian Cancer

SEAMON, LEIGH G. DO, MPH*; RICHARDSON, DEBRA L. MD; COPELAND, LARRY J. MD

Clinical Obstetrics & Gynecology:
doi: 10.1097/GRF.0b013e318248050d
Ovarian Cancer
Abstract

This chapter reviews some of the sentinel Gynecologic Oncology Group (GOG) ovarian trials, describes their rationale, provides summary tables for reference, and is organized into early ovarian cancer (GOG 1, 7601, 7602, 95, 157, 175, 212), advanced ovarian cancer optimal (2, 25, 52, 104, 114, 158, 172, 182, 178, 212, 252), and suboptimal disease (3, 22, 47, 97, 111, 162, 182, 218, 252, 262).

Author Information

*Department of Obstetrics, Gynecology and Women's Health, Division of Gynecologic Oncology, Spectrum Health Medical Group and Michigan State University College of Human Medicine, Grand Rapids, Michigan

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Texas Southwestern Medical Center, Dallas, Texas

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Center and Solove Research Institute, Columbus, Ohio

The authors declare that they have nothing to disclose.

Correspondence: Leigh G. Seamon, DO, MPH, Gynecologic Oncology, Lemmen-Holton Cancer Pavilion, Suite 2220, Grand Rapids, MI. E-mail: Leigh.Seamon@spectrumhealth.org

© 2012 Lippincott Williams & Wilkins, Inc.